Market Intelligence, Clinical Progress, and High-Purity Reagents for G2/M Checkpoint Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for WEE1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT & Mutant) | WEE1 Kinase Domain recombinant protein; high purity (>95%), Endotoxin <1EU/μg, sequence verified. Includes gatekeeper and pocket variants (e.g., dbSNP rs34412975, rs56411856). | View WEE1 Products |
| Gene Delivery | WEE1 Promise-ORF / Lentivirus for stable cell line construction; full-length ORF, HEK293 expressed. | View WEE1 Products |
| Pharmacodynamic Ab | Anti-WEE1 recombinant antibody for WB/IHC/IF pharmacodynamic detection; sequence verified. | View WEE1 Products |
| Validator | WEE1 siRNA set for target knockdown verification and assay specificity control. | View WEE1 Products |
| Related Target A | PKMYT1 — kinase family counter-screening and synergistic synthetic lethality. | View PKMYT1 Products |
| Related Target B | CHK1 (CHEK1) — parallel G2/M checkpoint kinase; combination partner and resistance bypass node. | View CHEK1 Products |
| Related Target C | PARP1 — synthetic lethality combination target within DNA damage response pathway. | View PARP1 Products |
| Related Target D | CDK1 — direct downstream substrate of WEE1; core pharmacodynamic marker. | View CDK1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | TarMart Advantage (Technical Spec) |
|---|---|
| Kinase selectivity screening (off-target liabilities) | High-purity WEE1 kinase domain (>95%) with native ATP-binding fold; homolog panel proteins (PKMYT1, CHK1) available for counter-screening, verified by mass spec and enzymatic assays. |
| Drug resistance surveillance (ATP-site mutations) | Rational design mutant panel including gatekeeper and pocket variants (e.g., dbSNP rs34412975, rs56411856); sequence verified, theoretical MW. |
| Cellular pharmacodynamic validation | Full-length WEE1 lentivirus (Promise-ORF) for stable integration into HEK293/HeLa lines; benchmark inhibitors and positive controls included. |
| Assay specificity control | WEE1 siRNA set included for target knockdown confirmation; validated siRNA for precise specificity checks. |
| High-throughput combination screening | Endotoxin-controlled (<1EU/μg) proteins suitable for long-term cellular synergy assays; active kinase domains expressed with optimized tags retaining high specific activity. |
Live WEE1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for WEE1 therapeutics is intensifying. Major players are shifting focus from first-generation pan-kinase inhibitors (e.g., adavosertib/AZD1775) toward next-generation selective ATP-competitive scaffolds and targeted protein degraders (PROTACs) to widen the therapeutic window and minimize hematological toxicities. As clinical-stage molecules define safety and efficacy boundaries in TP53-mutant tumors (ovarian, pancreatic, uterine serous carcinoma), the next wave targets combination regimens — with PARP inhibitors, platinum chemotherapies, and ATR/CHK1 pathway nodes — to overcome primary resistance and expand indications beyond gynecological malignancies. Zentalis (azenosertib) and Debiopharm (Debio 0123) are leading the next generation with improved selectivity and tolerability.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Kinase Inhibitor | AstraZeneca, Zentalis, Debiopharm | Ovarian cancer, pancreatic, TP53-mutant solid tumors | Selectivity assay (need high-purity active kinase & PKMYT1 counter-screen) |
| PROTAC / Targeted Degrader | Emerging biotechs | Refractory solid tumors | Degradation validation (need high-affinity antibodies and ORF constructs) |
| Combination Therapy (chemo / PARPi + WEE1i) | Academic / Pharma consortia | Solid tumors, hematologic malignancies (BRCA-mutant/HRD) | Synergy screening (reliable cellular knockdown via siRNA and stable cell lines) |
Key WEE1 Mutations and Resistance Prevention
Resistance to ATP-competitive WEE1 inhibitors can arise through mutations in the kinase domain. TarMart offers rationally designed mutant proteins covering clinically relevant variants, including gatekeeper mutations (dbSNP rs34412975) and pocket mutations (dbSNP rs56411856). These reagents enable early identification of resistance liabilities and support the development of next-generation inhibitors with broader mutant coverage.
Molecular Differentiation & Assay Strategy
To achieve best-in-class profile, WEE1 inhibitors must demonstrate:
- Selectivity against PKMYT1: First-generation inhibitors often co-target PKMYT1, leading to hematologic toxicity. Use high-purity WEE1 and PKMYT1 recombinant protein in enzymatic counter-screens.
- Optimal binding kinetics: Long residence time correlates with better in vivo efficacy. Use SPR/BLI with active kinase domains.
- For PROTACs: Rapid and specific degradation validation requires stable cell lines overexpressing WT/mutant WEE1 (use Promise-ORF constructs) and high-affinity antibodies.
TarMart’s integrated reagent ecosystem — from antigens and ORFs to antibodies and siRNA — directly supports each of these assay strategies.